Actively Recruiting
Evaluating Weekly NNC0487-0111 Injections Versus Low-Energy Diet and Placebo on Energy Metabolism in Adults with Overweight or Obesity
Led by Novo Nordisk A/S · Updated on 2026-10-01
120
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how the drug NNC0487-0111 affects the bodys energy use in adults living with overweight or obesity after they lose weight. The study compares the energy used by participants receiving this drug with those losing weight through a low-calorie diet and with those receiving a placebo without weight loss. This is a phase 1 randomized, placebo-controlled study aiming to understand energy metabolism changes following weight loss. Participants will be assigned to one of three groups one receives a weekly injection of NNC0487-0111, another receives a weekly injection of a placebo matching the drug, and the third follows a low-energy diet designed to reduce body weight. The drug and placebo are given subcutaneously once a week. The study period ranges from 12 to 26 weeks where these treatments or interventions are monitored. During the study, participants will undergo various assessments including measurements of sleeping metabolic rate, 24-hour energy expenditure, basal metabolic rate, resting metabolic rate, and diet-induced thermogenesis at baseline and between weeks 12 to 26. Researchers will track how these energy-related outcomes change to evaluate the effects of the drug and diet. Safety and compliance will also be monitored throughout the study, which is expected to last until 2028.
CONDITIONS
Brief Title
A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or Placebo
Research Team
N
Novo Nordisk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here